Head-to-head evidence
Eslicarbazepine acetate vs Fosphenytoin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Eslicarbazepine acetate · Aptiom
Marketed by Sumitomo Pharma and partners
NCT00957684 · Phase 3 · completed
The main study was randomized, quadruple-blind, placebo-controlled, and included 402 participants, with seizure frequency as a clinical primary endpoint. Although seizure frequency was lower in all eslicarbazepine groups than with placebo, the posted registry data do not state whether the prespecified primary comparison was statistically significant, so the result remains unclear.
Fosphenytoin
Marketed by Pfizer
NCT00908453 · Phase 3 · completed
The study assigned participants to fosphenytoin dose groups without randomization, blinding, or a comparator arm. Its primary safety endpoint cannot be assessed because the registry does not report results, so the evidence remains limited.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eslicarbazepine acetate's landscape · Fosphenytoin's landscape